The Effects of Resveratrol Treatment on Bcl-2 and Bax Gene Expression in Endometriotic Compared with Non-Endometriotic Stromal Cells

Roya KOLAHDOUZ-MOHAMMADI¹, Ali-Akbar DELBANDI²,³, Sepideh KHODAVERDI⁴, Soheila AREFI⁵,⁶, Tahereh ARABLOU¹, *Farzad SHIDFAR¹

1. Department of Nutrition, School of Public Health, Iran University of Medical Sciences, Tehran, Iran
2. Department of Immunology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran
3. Immunology Research Center, Institute of Immunology and Infectious Diseases, Iran University of Medical Sciences, Tehran, Iran
4. Endometriosis Research Center, Iran University of Medical Sciences, Tehran, Iran
5. Babman Hospital Infertility Center, Tehran, Iran
6. Genetics and In Vitro Assisted Reproductive (GIVAR) Center, Erfan Hospital, Tehran, Iran

*Corresponding Author: Email: shidfar.f@iums.ac.ir

(Received 11 Mar 2019; accepted 26 Jun 2019)

Abstract

Background: We aimed to examine resveratrol effects on gene expression of Bcl-2, Bax and Bcl-2/Bax ratio in endometrial stromal cells derived from women with and without endometriosis.

Methods: Endometrial tissues were obtained from 40 endometriotic patients and 15 non-endometriotic controls undergoing laparoscopic surgery or hysterectomy in the gynecology ward of Rassoul Akram Hospital, Tehran, Iran from 2015 to 2017. After the enzymatic digestion, eutopic (EuESCs) and ectopic (EESCs) endometrial stromal cells from patients with endometriosis as well as endometrial stromal cells from non-endometriotic controls (CESCs) were treated with or without resveratrol (100 µM) and the levels of Bcl-2, Bax and Bcl-2/Bax gene expression ratio in the cells from all origins were examined at 6, 24 and 48 h post-treatment by real-time PCR.

Results: Resveratrol treatment increased Bcl-2 expression in CESCs at 24 and 48 h and in EuESCs at 48 h (P<0.05), but had no significant effects on the expression of this gene in EESCs. On the other hand, resveratrol treatment increased Bax expression in EuESCs at 6 h and decreased its expression in EESCs at 48 h (P<0.05). Regarding the Bcl-2/Bax gene expression ratio, resveratrol treatment increased Bcl-2/Bax gene expression ratio in CESCs and EuESCs at 48 h (P<0.01). However, this treatment had no significant differential effect on Bcl-2 and Bcl-2/Bax gene expression ratio between CESCs and EuESCs at 48 h.

Conclusion: Resveratrol treatment significantly increased Bcl-2/Bax gene expression ratio in EuESCs and CESCs but had no significant effect in EESCs.

Keywords: Endometriosis; Resveratrol; Apoptosis; Gene expression; Antioxidant

Introduction

Endometriosis, defined as the presence of viable endometrial-like tissues, including glands and stroma outside the uterine cavity, is associated with pelvic pain, dysmenorrhea and infertility (1). Endometriosis is histologically categorized into
three distinct forms: ovarian endometriosis (endome-
triotrauma), peritoneal endometriosis and deeply
infiltrating endometriosis (DIP) (2). Regardless of
being a common and serious health problem in
women, the exact etiology of endometriosis re-
 mains unclear. Based on published studies, retro-
grade menstruation (Sampson theory) of endome-
trial cells with subsequent implantation and
growth of viable endometrium within the peri-
neal cavity have an important role in triggering and
developing the disease (1). Ample evidence indi-
cates that the endometrial cells from women with
and without endometriosis have different capaci-
ties to invade apoptosis (3), proliferate, implant
and survive in the ectopic locations (4).

Apoptosis in the eutopic endometrium of endo-
mertiotriotic patients was lower compared to non-en-
dometriotic patients. Moreover, ectopic endome-
trium of endometriotic patients showed less apop-
tosis compared with their eutopic counterparts (3, 5). Besides, early studies provided conflicting data
concerning the difference in anti-apoptotic B-cell
lymphoma/leukemia-2 (Bcl-2) and pro-apoptotic
Bax gene expression between normal endometrial
tissue and eutopic and/or ectopic endometrial tis-
sue in endometriotic women (6). Therefore, ma-
nipulation of programmed cell death processes by
enhancing endogenous or exogenous apoptotic
stimulants in the lesions could be used to treat en-
dometriosis.

In recent years, naturally occurring phytochemi-
cals such as resveratrol have gained considerable
attention because of their health-promoting prop-
erties (7). Resveratrol (trans-3,4',5-trihydroxystil-
bene, C14H12O3) is a phytoalexin synthesized by
plants in response to fungal infection or exposure
to ultraviolet light and is present in dietary prod-
ucts such as grapes and red wine (8). In the last
few decades, resveratrol and other stilbenes have
gained considerable attention, particularly in in-
vitro and preclinical studies due to their antioxi-
dant, anti-inflammatory, anti-neoplastic and other
health-promoting effects (9).

Therapeutic effects of resveratrol on endometrio-
sis was first described by Bruner-Tran et al in 2011
(10). From that moment, the interest in this natu-
ral compound has grown extremely and many re-
searchers tried to find protective mechanisms of
resveratrol on endometriosis. Resveratrol controls
the development of endometriosis by suppression
of proliferation in endometriotic lesions (10, 11),
induction of apoptosis (10, 11), reduction of in-
flammation (12, 13), angiogenesis (12, 14, 15) and
oxidative stress (16). With regard to apoptosis,
previous studies examined the effects of resvera-

trol on experimental endometriotic mice models
gained conflicting results (10, 11, 17). However,
the effect of resveratrol treatment on apoptosis in
endometriotic stromal cells was examined in just
one study (18). In that study, resveratrol treatment
did not induce apoptosis in endometriotic stromal
cells.

These findings encouraged us to investigate the
gene expression of Bcl-2, Bax and Bcl-2/Bax ratio
in eutopic (EuESCs) and ectopic (EESCs) endo-
metrial stromal cells from patients with peritoneal
endometriosis and endometrial stromal cells from
non-endometriotic controls (CESCs).

Materials and Methods

Patient recruitment and sample collection

Forty women with peritoneal endometriosis and
15 women without endometriosis who underwent
laparoscopic surgery or hysterectomy in the gyn-
ecology ward of Rassoul Akram Hospital, Tehran,
Iran (January 2015 to April 2017) were enrolled in
this study. All eligible women were of reproduc-
tive age (19-45 yr old), at the proliferative phase of
the menstrual cycle, had normal menstrual cycles
and had no history of hormonal treatment, preg-
nancy, breastfeeding, or using antioxidant supple-
ments within the last three months before sam-
ping. Patients with pelvic inflammatory disease,
adenomyosis and suspected or ascertained diagno-
sis of malignancy were excluded. All patients with
endometriosis were classified into stage III-IV ac-

cording to the revised American Fertility Society
system (19).

All experimental procedures were approved by
Human Ethics Committees of the Iran University
of Medical Sciences (No: IR.IUMS.REC.1395.28108) and signed informed
consent was obtained from each participant before enrolling in the study. Ectopic and eutopic endometrial samples were obtained through laparoscopic sampling and biopsy curette, respectively. In parallel, small fragment of the excised tissues were examined histologically for confirmation of endometriosis.

**Isolation of endometrial stromal cells (ESCs) and cell culture**

Fresh endometriotic tissues were collected in sterile Dulbecco’s modified Eagle’s medium (DMEM–F12 (Gibco, Grand Island, NY, USA) containing antibiotics and immediately transferred in cold chain to the laboratory, where minced into small pieces and digested at 37 °C for 120 min in DMEM/F-12 containing 100 U/ml penicillin and 100 µg/ml streptomycin, 2 mg/ml of type I collagenase (Sigma-Aldrich, St Louis, MO, USA) and 300 µg/ml of deoxynuclease I (Takara, Tokyo, Japan) with intermittent vortexing every 15 min (20). The obtained ESCs were then cultured and allowed to propagate not beyond passage three. Some samples were lost due to contamination or absence of enough cell growth especially in case of EESCs. Finally, cells from 13 eutopic and 11 eutopic endometrial tissues of endometriotic patients and 11 eutopic endometrial tissue from non-endometriotic patients were used in this study. Purity of isolated ESCs was assessed by flowcytometric analysis using a panel of antibodies. The ESCs were characterized as CD10⁺, CD73⁺, CD105⁺, CD44⁺, CD34⁻ and CD45⁻ cells.

**MTT assay**

To investigate the safety dose of resveratrol, methyl thiazolyl tetrazolium (MTT) (Danesh Azma, Iran) assay was performed (21). Resveratrol (Sigma-Aldrich, St Louis, MO, USA) was dissolved in ethanol. Approximately 2×10⁴/well EuESCs from 4 endometriotic patients were seeded in duplicate in 96-well plates (SPL, Korea) and cultured for 24 h. After this time, EuESCs were treated in the presence or absence of resveratrol (12.5, 25, 50, 100, 200 and 400 µM). One h later, cells were stimulated with lipopolysaccharide (LPS) (100 ng/ml) (22, 23) as an inducer of apoptosis (24) and incubated in an incubator at 37 °C in a humidified, 5% CO₂. The cytotoxic activity was determined after 24 and 48 h. Following 24 h incubation period, the medium was removed and 100 µl of fresh medium containing 12 mM MTT stock solution was added to all wells and plates were incubated for 4 h at 37 °C. Thereafter, medium was removed from the wells and 50 µl of MTT solvent was added to each well. After ensuring that all formazan crystals were dissolved, the absorbance was measured at 570 nm using a microplate ELISA reader (Bio-Tek Instruments Inc., Vermont, USA). The viability of the cells calculated using the following equation:

%Viability = [(OD of treated cells - OD of MTT solvent) / (OD of untreated cells - OD of MTT solvent)] × 100

**Treatment of ESCs with resveratrol**

In a pilot study, different concentrations of resveratrol ranging from 25–100 µM and also the time interval for the addition of LPS to the resveratrol-treated cells were set up. A collectively concentration of 100 µM for resveratrol was selected because this concentration has been shown to suppress cell proliferation or modulate biochemical processes in cancer cell lines (25). Thus, 30×10⁴/well ESCs were seeded in 24-well plates and after 3 h, cells were treated with 100 µM resveratrol or ethanol as vehicle control. One h later, 100 ng/ml LPS (23) was added to each well and cells were incubated for 6, 24 and 48 h.

**RNA extraction and cDNA synthesis**

Total RNA from treated and untreated ESCs were extracted using the TRIZOL reagent (QIAGEN, Germany) according to the supplier’s protocol. The quantity of the extracted RNA was determined at an absorbance wavelength of 260/280 using a NanoDrop 2000 spectrophotometer (Thermo Fisher Scientific, Waltham, MA, USA). Reverse transcription of RNA (1 µg) was performed using a Revert Aid First Strand cDNA Synthesis Kit (Thermo Fisher Scientific, Waltham, MA, USA) according to the manufacturer’s instructions. The expressions of the genes of interest
were normalized using glyceraldehyde 3-phosphate dehydrogenase (GAPDH) as a housekeeping gene. The following primers and annealing temperatures were used for amplification; Bcl-2: forward primer (F) 5’- ATCGCCCTTG-GATGACTGAGT-3’ and reverse primer (R) 5’- GCCAGAGAAATCAACAGAGGC-3’ (62°C) (26); Bax: (F) 5’- CCCTTTC- GCCAGGTTTCATCCA-3’ and (R) 5’- CTTGAGACACTCGCTAGCTTCTTG-3’ (60°C) (27); GAPDH: (F) 5’- GCA CCG TCA AGG CTG AGA AC-3’ and (R) 5’- TGG TGA AGA CGC CAG TGG A-3’ (58°C) (28). The template and primer pairs were mixed with SYBER Green PCR Master Mix (BioFACT, South Korea) and real-time PCR was performed using a Rotor-Gene 3000 (Corbett Research, Sydney, Australia) with preliminary hold at 95 °C for 15 min, followed by 40 cycles of 95 °C for 20 sec, annealing and elongation for 40 sec and finally melting step was from 60 to 99 °C. Melting curve analysis was carried out to ensure the specificity of amplification.

Statistical analysis
The statistical analysis of data was performed using GraphPad Prism software (ver. 6). The Kolmogorov–Smirnov distribution test was used in order to assess data normality. Based on the non-parametric distribution of data, Wilcoxon and Mann-Whitney U tests were used for comparison of variables within and between groups, respectively. For the comparison of more than two independent variables, Kruskal–Wallis test was used. In the case of significant differences between the study groups, differential effect was applied. P-value of <0.05 was considered as statistically significant.

Results
The effect of resveratrol on EuESCs viability
The viability of EuESCs was determined by MTT assay. Cells were treated with resveratrol (12.5-400 µM) for 24 and 48 h. Resveratrol treatment with concentrations lower than 100 µM for up to 48 h had no effect on EuESCs viability while treatment of these cells with 200 µM of resveratrol for 48 h, reduced EuESCs viability to 50% (P<0.001) (Fig. 1).

![Fig. 1: The effect of resveratrol on EuESCs viability. EuESCs were treated with and without resveratrol (12.5-400 µM) for 24 and 48 h in the presence of LPS (100 ng/ml). Cell viability was examined by MTT assays. Data were represented as medians (interquartile range) of two separate experiments. Statistical comparisons were made by an analysis of variance (two-way ANOVA), with a 95% confidence interval followed by Tukey post hoc test to identify significant differences between mean values of the target cells and the controls. In the figure, “a” indicates “no significant differences”; while “**∗∗∗” indicates “P<0.001”. EuESCs, eutopic endometrial stromal cells; LPS, lipopolysaccharide; MTT, methylthiazolyl tetrazolium](http://ijph.tums.ac.ir)

The effect of resveratrol on Bcl-2 gene expression
As Fig 2 shows, resveratrol treatment increased Bcl-2 gene expression in CESCs at 24 (P<0.05; Fig. 2B) and 48 h (P<0.01; Fig. 2C) and in EuESCs at 48 h (P<0.01; Fig. 2C), but had no significant effects on the expression of this gene in EESCs. Furthermore, resveratrol treatment had no significant differential effect on increased Bcl-2 gene expression between EuESCs and CESCs at 48 h (Fig. 2D).

The effect of resveratrol on Bax gene expression
Resveratrol treatment increased Bax gene expression in EuESCs at 6 h (P<0.05; Fig. 3A) and decreased its expression in EESCs at 48 h (P<0.05; Fig. 3C).
Fig. 2: Quantitative RT-PCR gene expression of Bcl-2 in CESCs, EuESCs and EESCs treated with or without resveratrol for 6, 24 and 48 h. CESCs from non-endometriotic controls (n = 11), EuESCs (n = 13) and EESCs (n = 11) from endometriotic patients were cultured in the presence or absence of resveratrol for 6 (A), 24 (B) and 48 h (C). The bar graph indicates the fold change of Bcl-2 mRNA expression. (D) Differential effect of resveratrol on EuESCs and CESCs at 48 h were calculated as the ratio of Bcl-2 gene expression in the presence and absence of resveratrol. Data are expressed as means ± SEM. *P<0.05, **P<0.01. CESCs, control endometrial stromal cells; EuESCs, eutopic endometrial stromal cells; EESCs, ectopic endometrial stromal cells.

Fig. 3: Quantitative RT-PCR gene expression of Bax in CESCs, EuESCs and EESCs treated with or without resveratrol for 6, 24 and 48 h. CESCs from non-endometriotic controls (n = 11), EuESCs (n = 13) and EESCs (n = 11) from endometriotic patients were cultured in the presence or absence of resveratrol for 6 (A), 24 (B) and 48 h (C). The bar graph indicates the fold change of Bax mRNA expression. Data are expressed as means ± SEM. Statistical comparisons were made by Wilcoxon matched-pairs signed rank test. *P < 0.05. CESCs, control endometrial stromal cells; EuESCs, eutopic endometrial stromal cells; EESCs, ectopic endometrial stromal cells.

The effect of resveratrol on Bcl-2/Bax gene expression ratio

Resveratrol treatment increased Bcl-2/Bax gene expression ratio in CESCs and EuESCs at 48 h (P<0.01 and P≤0.001 respectively; Fig. 4C) but
had no significant effect on Bcl-2/Bax gene expression ratio in EESCs (Fig. 4). Besides, resveratrol treatment had no significant differential effect on increased Bcl-2/Bax gene expression ratio between EuESCs and CESCs at 48 h (Fig. 4D).

Fig. 4: Quantitative RT-PCR gene expression of Bcl-2/Bax ratio in CESCs, EuESCs and EESCs treated with or without resveratrol for 6, 24 and 48 h. CESCs from non-endometriotic controls (n = 11), EuESCs (n = 13) and EESCs (n = 11) from endometriotic patients were cultured in the presence or absence of resveratrol for 6 (A), 24 (B) and 48 h (C). The bar graph indicates the fold change of Bcl-2/Bax mRNA expression ratio. (D) Differential effect of resveratrol on EuESCs and CESCs at 48 h were calculated as the ratio of Bcl-2/Bax gene expression in the presence and absence of resveratrol. Data were represented as mean ± SEM. **P < 0.01 and ***P ≤ 0.001. CESCs, control endometrial stromal cells; EuESCs, eutopic endometrial stromal cells; EESCs, ectopic endometrial stromal cells

**Discussion**

In this study, resveratrol treatment increased Bcl-2/Bax gene expression ratio in EuESCs and CESCs. To our knowledge, this is the first report evaluating the effects of resveratrol on apoptosis by investigating Bcl-2, Bax and Bcl-2/Bax gene expression ratio in ESCs. Resveratrol has been reported to exert a variety of biological effects, but the underlying mechanisms regarding apoptosis are not well understood. Recently, conflicting results were reported regarding induction of apoptosis by resveratrol in endometriosis (10, 11, 17, 18). Bruner-Tran et al. have recently demonstrated that resveratrol increased TUNEL staining of endometrial implants (10). Besides, BALB/c mice underwent surgical induction of endometriosis. Resveratrol treatment in this study, significantly increased apoptosis in the lesions (11). On the other hand, in a randomized study in a mouse model of endometriosis, resveratrol treatment had no effect on caspase-3-positive apoptotic cells in endometriotic lesions (17). Besides, resveratrol treatment did not induce apoptosis measured by annexin V-FITC in endometrial stromal cells (18). On the other hand, in our study resveratrol treatment significantly increased Bcl-2/Bax gene expression ratio in EuESCs and CESCs.

One explanation for such differing results could be explained by possible differences in the methodology. In animal models of endometriosis, endometriotic lesions were induced differently. Some induced endometriotic lesions surgically using endometrial tissues from women without endometriosis (10) or used uterine tissue from donor mice into the peritoneal cavity of recipient mice.
without using endometriotic tissue of human origin (17). Endometrium from women with endometriosis and endometriotic implants have some major differences compared with the normal endometrium of non-endometriotic women (29). Furthermore, induction of apoptosis observed in mouse model of endometriosis, was not the direct result of resveratrol, but was secondary to the effect of resveratrol on suppression of vascularization (11,17) and invasiveness (10).

There is a plethora of evidence suggesting an up-regulation of anti-apoptotic genes and reciprocal down-regulation of the genes regulating the apoptosis pathway in endometriotic stromal cells and resistance of these cells to apoptosis (30). Besides apoptosis, oxidative stress plays an important role in endometriosis (31). Presence of macrophages, iron or environmental contaminants in the peritoneal fluid of some women leading to oxidative stress, tissue growth and endometriosis (32). Furthermore, positive association between oxidative stress and endometriosis have been found in some studies (31). Increase in reactive oxygen species (ROS) production is associated with apoptosis (33). However, the magnitude of this effect will depend upon the cellular genetic background, the types and levels of the specific ROS involved and duration of the oxidative stress (34). On the other hand, many inhibitors of apoptosis have antioxidant activities or enhance cellular antioxidant defenses (35). Diets depleted of the antioxidants selenium and α-tocopherol were enhanced apoptosis and inhibited brain tumor growth in transgenic mouse model (36). In our study resveratrol as a potent inhibitor of ROS production (37), increased Bcl-2/Bax gene expression ratio in EuESCs and CESCs. Similarly, in other studies resveratrol treatment attenuated oxidative stress-induced cell death in cultured rat pheochromocytoma (PC12) cells (38) and human neuroblastoma cell line SH-SY5Y (39).

Another explanation for our findings could be explained by the role played by growth factors as an epidermal growth factor (EGF) and other growth factors stimulate endometriotic stromal cell’s growth (40) and inhibit resveratrol’s action on both ERK1/2 activation and the induction of apoptosis via the p53 pathway in cancer cells (41). On the other hand, EESCs and EuESCs altered responses to apoptosis in our study could be explained by differences in the microenvironment and inflammatory condition of peritoneal cavity of endometriotic patients that affecting endometriotic cell’s responses to nutritional interventions (20, 26).

A key strength of this study is that we used a large sample of the study subjects, and all our patients were examined in the same phase of the menstrual cycle. However, there are some limitations in our study. First, it may be essential to evaluate resveratrol effect in combination with other antioxidants in a long period of time. The second limitation was that we did not assess protein expression of apoptotic molecules and apoptosis.

**Conclusion**

Resveratrol treatment increased Bcl-2/Bax gene expression ratio in EuESCs and CESCs but had no effect on EESCs. Although apoptosis has an important role in pathophysiology of endometriosis, but further in vitro and in vivo studies are warranted to fully investigate resveratrol effects on cell proliferation, invasion, adhesion and other factors related to the pathogenesis of endometriosis.

**Ethical considerations**

Ethical issues (Including plagiarism, informed consent, misconduct, data fabrication and/or falsification, double publication and/or submission, redundancy, etc.) have been completely observed by the authors.

**Acknowledgements**

This study was funded by Iran University of Medical Sciences, Tehran, Iran (grant No. IR.IUMS.REC.1395.28108). The authors would like to thank all patients who participated in this research.
Conflict of interest

Authors declare that there is no conflict of interest.

References


